Sensei Biotherapeutics, Inc.
NASDAQ:SNSE
0.4055 (USD) • At close April 17, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.571 | 1.808 | 0.685 | 0.209 | 0.073 | 0.044 |
| Gross Profit
| 0 | -0.571 | -1.808 | -0.685 | -0.209 | -0.073 | -0.044 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 18.627 | 18.299 | 30.383 | 21.662 | 11.185 | 8.35 | 8.227 |
| General & Administrative Expenses
| 13.036 | 18.665 | 19.805 | 15.82 | 7.528 | 4.085 | 4.513 |
| Selling & Marketing Expenses
| 0 | 0.1 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 13.036 | 18.765 | 19.805 | 15.82 | 7.528 | 4.085 | 4.513 |
| Other Expenses
| 0.951 | 0 | 1.6 | 0.688 | -0.649 | -0.001 | 0.028 |
| Operating Expenses
| 32.614 | 37.064 | 50.188 | 37.482 | 18.713 | 12.435 | 12.74 |
| Operating Income
| -32.614 | -37.064 | -50.188 | -37.482 | -19.451 | -12.435 | -12.74 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 2.457 | 2.963 | 1.6 | 0.688 | -0.649 | -4.305 | -0.299 |
| Income Before Tax
| -30.157 | -34.101 | -48.588 | -36.794 | -20.1 | -16.74 | -13.039 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 0.219 | 0.67 | 0.529 | 2.255 | 0.299 |
| Net Income
| -30.157 | -34.101 | -48.807 | -37.464 | -20.629 | -18.995 | -13.039 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.2 | -1.22 | -1.59 | -1.35 | -0.67 | -0.65 | -19.03 |
| EPS Diluted
| -1.2 | -1.22 | -1.59 | -1.35 | -0.67 | -0.65 | -19.03 |
| EBITDA
| -32.614 | -33.386 | -46.561 | -36.797 | -18.504 | -12.362 | -12.696 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |